J&J Baby Powder Gave Women Cancer — What Victims Can Claim

Johnson & Johnson faces more than 68,000 active lawsuits over its talc-based baby powder, with plaintiffs alleging the company sold asbestos-contaminated products for decades while knowing the risks. The cancers tied to these products, primarily ovarian cancer and mesothelioma, have devastated thousands of women and their families across the United States.

The litigation is consolidated in the federal multidistrict litigation MDL-2738 in the U.S. District Court for the District of New Jersey, overseen by Judge Michael Shipp, making this the largest active MDL in the American court system. Three separate bankruptcy attempts by J&J subsidiaries have all failed, and the case is now heading toward jury trials following a formal bellwether trial program launched in 2025.

Johnson & Johnson Talc Lawsuit Timeline and Updates

1894 — J&J Introduces Baby Powder

Johnson & Johnson launched its talc-based baby powder in 1894. The product became one of the most trusted consumer goods in American households. Talc was valued for its softness and moisture-absorbing properties, and J&J eventually purchased its own talc mines to control supply, according to reporting by The New Yorker.

1930s to 1970s — Internal Records Show Early Asbestos Awareness

Court documents revealed that internal J&J records indicated awareness of potential asbestos contamination in talc as far back as the 1930s. By the 1970s, at least one company researcher who identified asbestos in the product was dismissed. The U.S. Food and Drug Administration began implementing limits on asbestos in cosmetic talc products in 1976.

A 2018 Reuters investigation uncovered that J&J withheld test results from the FDA showing elevated asbestos levels in its talc, including one batch where asbestos was described as present at levels reported as “rather high.” At least three separate lab tests from 1972 to 1975 confirmed asbestos contamination, but none of those results were disclosed to regulators.

1971 — Asbestos Injections in Prison Inmates

According to the BMJ research journal, Johnson & Johnson funded a study in 1971 in which prison inmates, most of whom were Black, received asbestos injections into their skin. The study compared the effects of asbestos with baby powder, raising serious ethical and legal concerns about the company’s conduct toward marginalized populations.

2009 — First Wave of Ovarian Cancer Lawsuits Filed

Lawsuits against J&J began mounting in 2009, with plaintiffs alleging that prolonged perineal use of talcum powder caused ovarian cancer. Women who had used Baby Powder or Shower to Shower for feminine hygiene for years or decades formed the core of the plaintiff class.

2013 — Internal Draft Acknowledges Contamination Risk

The Reuters investigation uncovered a 2013 edited internal draft of a company website statement that acknowledged the possibility that J&J’s talc could have been contaminated with asbestos. The draft was never published. Internal emails from 2003 described Baby Powder as “a sacred cow” within the company, reflecting how central the product was to J&J’s brand identity and the institutional reluctance to address contamination risk.

2016 — Landmark California Verdict

A California jury awarded $70 million to Deborah Giannecchini, who attributed her ovarian cancer to years of using Johnson’s Baby Powder. Plaintiff attorneys presented evidence that J&J failed to warn consumers about asbestos risks. The verdict marked a turning point in the litigation, demonstrating that juries were prepared to hold J&J accountable.

2018 — Record $4.69 Billion Missouri Verdict

A St. Louis, Missouri jury awarded $4.69 billion to 22 women who alleged J&J’s talc-based products caused their ovarian cancer. This remains the largest single talc-related jury award in history. The verdict motivated thousands more plaintiffs to come forward, accelerating the growth of the MDL.

2020 — J&J Discontinues Talc Baby Powder in North America

Johnson & Johnson pulled its talc-based baby powder from shelves in the United States and Canada in 2020, citing declining demand and what the company called “misinformation around the safety of the product.” The admission that demand had collapsed under legal and reputational pressure was widely seen as an implicit acknowledgment of the problem.

2021 — LTL Management Files for Bankruptcy (Texas Two-Step Attempt 1)

By 2021, over 38,000 lawsuits had been filed. To limit its financial exposure, J&J created a subsidiary called LTL Management LLC and transferred all talc-related liabilities to it. LTL then filed for Chapter 11 bankruptcy in the U.S. Third Circuit Court of Appeals, pausing the litigation. This maneuver, called the Texas Two-Step, allows financially healthy companies to offload liabilities into a newly created entity that then files for bankruptcy.

2022 — J&J Discontinues Talc Baby Powder Globally

In 2022, J&J extended the discontinuation internationally, replacing talc in all of its baby powder products with cornstarch. The global pullout effectively ended the sale of talc-based Johnson’s Baby Powder after more than 125 years on the market.

January 2023 — Third Circuit Rejects First Bankruptcy Attempt

The U.S. Court of Appeals for the Third Circuit ruled that LTL Management’s bankruptcy filing was not made in good faith because J&J itself was not in financial distress. The court dismissed the bankruptcy attempt, ruling that a healthy company could not exploit bankruptcy protections to shield itself from mass tort liability.

April 2023 — Second Bankruptcy Attempt Dismissed

J&J tried again in April 2023, filing a second LTL bankruptcy in the U.S. Bankruptcy Court for the District of New Jersey. That court dismissed the effort in July 2023 under the same reasoning: J&J had no genuine financial need for bankruptcy protection.

July 2024 — IARC Classifies Talc as Probable Carcinogen

The International Agency for Research on Cancer, the cancer research arm of the World Health Organization, classified talc as a Group 2A carcinogen in July 2024, meaning it probably causes cancer. The IARC’s assessment was based on evidence that talc, particularly when contaminated with asbestos during mining, poses an elevated cancer risk. This classification provided significant scientific backing for the plaintiff litigation.

September 2024 — Red River Talc Files Third Bankruptcy (Texas Two-Step Attempt 3)

J&J created a new subsidiary, Red River Talc LLC, and filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Southern District of Texas under Judge Christopher Lopez. The company offered a proposed settlement of $8 to $9 billion to be paid over 25 years to resolve all current and future ovarian cancer claims. J&J reported that approximately 83% of current claimants supported the plan, which required a 75% approval threshold. The U.S. Department of Justice filed a motion to dismiss, describing the filing as a “textbook example of bad faith bankruptcy.”

October 2024 — MDL Surpasses 58,000 Cases

In October 2024 alone, 146 new cases were added to the MDL, bringing the total to 58,198 pending cases. The total number of talcum powder lawsuits filed across all venues exceeded 62,000 by year’s end.

December 2024 — Bankruptcy Trial Begins in Texas

The bankruptcy trial commenced on February 19, 2025 before Judge Lopez in Texas. The trial focused on allegations of bad-faith filing and a flawed claimant voting process. Plaintiff lawyers were divided: some seeking resolution after years of litigation, others firmly opposed to the bankruptcy strategy.

March 31, 2025 — Third Bankruptcy Attempt Rejected

Judge Lopez dismissed the Red River Talc bankruptcy case on March 31, 2025. The ruling condemned J&J’s manipulation of the claimant vote, stating the company imposed an “unreasonably short voting time to get to 75% at any cost.” This marked the third consecutive failure of J&J’s bankruptcy strategy. With all three attempts exhausted, litigation returned to federal and state courts.

April 2026 — Lancet Retracts Key J&J-Funded Safety Study

The medical journal The Lancet retracted a 1977 commentary that had been widely cited in defense of cosmetic talc safety. Editors discovered the author was a paid consultant for Johnson & Johnson, a financial relationship never disclosed at the time of publication. The author had also shared pre-publication drafts directly with the company. The retraction removed a cornerstone of J&J’s scientific defense and immediately strengthened the plaintiff litigation across the MDL.

June 2026 — MDL Tops 68,000 Cases; Bellwether Trial Selected

The Johnson & Johnson talc MDL reached 68,029 pending cases as of June 2, 2026, making it the largest active MDL in the federal court system. The case Judkins v. Johnson & Johnson was officially selected as the first federal bellwether trial in the MDL. The case involves a New Hampshire woman alleging decades of talc use caused her ovarian cancer. The bellwether selection came alongside ongoing court-ordered mediation sessions before appointed mediator Fouad Kurdi, who was named to the role by Judge Shipp in March 2026.

What the Lawsuit Alleges

Plaintiffs allege that Johnson & Johnson knowingly sold talc-based products contaminated with asbestos for decades and failed to warn consumers of the cancer risk. The core claims fall into three categories: defective product design, failure to warn, and fraudulent concealment.

Talc is a mineral that can become naturally contaminated with asbestos during the mining process, as the two minerals often form in proximity underground. When women applied Baby Powder or Shower to Shower for perineal hygiene over many years, asbestos fibers could be inhaled or absorbed by the body, potentially reaching the ovaries and lungs through the bloodstream or lymphatic system.

Internal J&J documents produced during discovery showed the company was aware of asbestos contamination in its talc supply as far back as the 1930s. Despite this knowledge, J&J continued selling the products without warnings, withheld test results from the FDA, and suppressed research linking talc use to cancer. According to the Reuters investigation, the company also lobbied for FDA testing policies that would use less sensitive detection methods, making it harder to identify asbestos contamination.

The 2021 National Council of Negro Women also sued J&J for deceptive marketing practices, alleging the company disproportionately targeted Black women in its advertising campaigns while knowing the product posed cancer risks to those users.

Who Qualifies to File a Johnson & Johnson Lawsuit

The MDL in New Jersey primarily handles ovarian cancer and mesothelioma claims. Mesothelioma claims from talc use have generally proceeded in state courts alongside the federal MDL. Products named in recent lawsuits include Johnson’s Baby Powder and Shower to Shower, both manufactured and marketed by J&J’s consumer division.

Men who used talc-based products have also filed mesothelioma claims, though the bulk of plaintiff claims come from women who used the products for perineal hygiene over extended periods. Cosmetic product users more broadly have also been named in certain state court proceedings.

Injuries and Cancers Covered

The two primary cancer types at the center of J&J talc litigation are ovarian cancer and mesothelioma. Ovarian cancer accounts for the large majority of MDL claims, with more than 60,000 active cases. Mesothelioma claims, while fewer in number, have produced the most dramatic individual verdicts.

Malignant peritoneal mesothelioma, a cancer of the lining of the abdominal cavity, has featured prominently in recent trial verdicts. Cherie Craft, a Baltimore plaintiff, was awarded $1.59 billion by a Baltimore City Circuit Court jury in December 2025 after developing peritoneal mesothelioma from daily use of Johnson’s Baby Powder.

Other eligible diagnoses in the litigation include pleural mesothelioma, a cancer of the lung lining; pericardial mesothelioma; endometrial cancer; fallopian tube cancer; and primary peritoneal cancer. Plaintiffs must demonstrate a documented history of talc product use alongside a confirmed cancer diagnosis.

Scientific Evidence Behind the Claims

The scientific case against J&J’s talc rests on two pillars: epidemiological studies linking talc use to ovarian cancer rates, and physical evidence of asbestos in J&J’s talc supply.

In May 2026, Dr. Rebecca Smith-Bindman, an epidemiology professor at the University of California, San Francisco, testified in the Los Angeles bellwether trial that multiple studies show an elevated ovarian cancer risk in women who frequently used talc products for feminine hygiene. Her testimony referenced studies dating back to 1982 and a 2024 National Institute of Environmental Health Sciences study involving more than 50,884 women.

A new NIH study published in the Journal of Clinical Oncology linked talcum powder use to ovarian cancer, potentially strengthening the plaintiff litigation and affecting settlement calculations. The IARC’s July 2024 classification of talc as a Group 2A probable carcinogen added institutional scientific weight to the plaintiff position.

Physical evidence from J&J’s own internal records supported the contamination claims. Court documents produced during discovery showed the company knew since the 1930s about asbestos contamination in talc, failed to successfully remove it, withheld positive test results, and destroyed evidence of asbestos findings.

The Three Failed Bankruptcy Attempts — What the Texas Two-Step Was

J&J’s repeated use of bankruptcy as a litigation management tool drew national attention and bipartisan criticism. The strategy, known as the Texas Two-Step, works as follows: a large, financially healthy company creates a subsidiary through a corporate restructuring and transfers all mass tort liabilities to that new entity. The subsidiary then files for Chapter 11 bankruptcy, which automatically pauses ongoing litigation and forces all claims into a single, controlled bankruptcy proceeding.

J&J executed this maneuver three times between 2021 and 2025, each time under a different subsidiary name: LTL Management LLC (2021), LTL Management LLC again (2023), and Red River Talc LLC (2024). All three attempts were ultimately rejected by the courts.

The Third Circuit Court of Appeals rejected the first attempt in January 2023, finding LTL’s filing lacked good faith because J&J faced no genuine financial distress. The second attempt in New Jersey was dismissed in July 2023 under similar reasoning. The third attempt, filed in Texas, was rejected by Judge Lopez on March 31, 2025, after he found J&J had manipulated the claimant voting process to reach the 75% approval threshold required for the plan to proceed.

The Department of Justice filed a motion to dismiss that third attempt, calling it a “textbook example of bad faith bankruptcy.” The failure of all three attempts left J&J facing individual trials across state and federal courts with no bankruptcy escape route remaining.

What J&J Knew and When — A Corporate Concealment Timeline

The internal document record in this litigation is among the most damaging produced in any modern product liability case. Court filings across multiple proceedings have established the following sequence of corporate knowledge and concealment.

By the 1930s, internal records showed awareness of potential asbestos contamination in the company’s raw talc supply. The minerals asbestos and talc form in geological proximity, and contamination during mining was a known industry risk. Despite this, J&J continued sourcing talc from the same mines for decades.

In the 1970s, at least one J&J researcher who identified asbestos in baby powder was fired. Between 1972 and 1975, three separate laboratories found asbestos in J&J talc samples, with one result described as “rather high.” None of these findings were disclosed to the FDA.

In 1976, when the FDA began regulating asbestos levels in cosmetic talc, J&J lobbied for testing methods that were less sensitive to asbestos detection, making it easier for contaminated products to pass regulatory review.

In 1971, J&J funded research using prison inmates, most of whom were Black, who were injected with asbestos to study its effects compared to baby powder. The study raised severe ethical concerns and reflected the company’s willingness to conduct asbestos research internally while publicly denying contamination risks.

In 2013, an internal draft of a company website statement acknowledged the possibility of past asbestos contamination in J&J’s talc but was never published. The concealment continued until the 2018 Reuters investigation broke the story publicly.

The April 2026 Lancet retraction removed the 1977 safety commentary that J&J had leaned on for decades. The author of that commentary was a paid J&J consultant, a conflict of interest never disclosed in the journal. The retraction meant that one of the most frequently cited scientific supports for J&J’s position no longer had peer-reviewed standing.

Major Jury Verdicts

Settlement Status and Expected Payouts

No global settlement has been reached as of June 2026. J&J’s three bankruptcy-based settlement proposals, which ranged from $6.48 billion to $9 billion, were all rejected by the courts. Court-appointed mediator Fouad Kurdi is overseeing ongoing settlement discussions under Judge Shipp’s order, with both sides required to participate with representatives carrying full settlement authority.

Bloomberg Intelligence analysts have estimated J&J’s total exposure across all claims at up to $11 billion. The company has also settled separately with 42 states and the District of Columbia for $700 million to resolve deceptive talc marketing claims, though that agreement does not affect individual MDL lawsuits.

Individual payout estimates for claimants range widely depending on cancer type, severity, and evidence strength:

These ranges are estimates drawn from law firm analyses and prior verdicts. Actual settlement payouts, if a global resolution is reached, will depend on tier criteria established in the settlement plan and the total volume of qualifying claims.

Bellwether Trials — What They Mean for Claimants

A bellwether trial is a test case selected from the broader MDL to go to trial first. The verdict does not bind other plaintiffs, but it provides both sides with a preview of how juries respond to the evidence, which directly influences settlement negotiations across the entire litigation.

The California coordinated ovarian cancer proceedings in Los Angeles Superior Court produced the first major bellwether results. In December 2025, a jury awarded $40 million combined to two women in the first California bellwether. In June 2026, a second California bellwether resulted in a defense verdict for J&J by a 10-2 vote, making the California record split: one plaintiff win, one defense win.

In the federal MDL, Judkins v. Johnson & Johnson was selected as the first federal bellwether trial in June 2026. The case involves a New Hampshire woman alleging ovarian cancer caused by decades of talc use. The federal bellwether carries particular weight because outcomes in the MDL tend to set the floor and ceiling for global settlement negotiations. A plaintiff win in Judkins would dramatically increase pressure on J&J to reach a global resolution. A defense verdict would give J&J leverage to resist settlement demands.

Philadelphia has also established a separate mass tort program for ovarian cancer talc cases, with bellwether trials scheduled for 2026.

J&J’s Defense — What the Company Claims

Johnson & Johnson consistently maintains that its talc products are safe and free from asbestos contamination. The company argues that its testing showed good faith safety efforts over decades and that plaintiffs lack the evidence needed to establish causation.

In the second California bellwether in June 2026, J&J’s counsel argued that asbestos contamination in talc at the levels alleged by plaintiffs would require a broad worldwide cover-up involving scientists, academics, regulators, and independent researchers. The defense pointed to studies of Italian talc miners as showing no elevated mesothelioma risk.

J&J also argues that California law limits failure-to-warn claims where the product user did not read the label, and it has relied heavily on independent laboratory testing results that found no asbestos in its talc samples.

However, J&J’s defense position has been significantly weakened by the April 2026 Lancet retraction, the IARC’s Group 2A classification, and the stream of plaintiff verdicts from juries that reviewed the company’s own internal documents.

Despite claiming its products are safe, J&J settled 95% of mesothelioma cases outside of court, spending approximately $1 billion in litigation costs, and has spent years attempting bankruptcy settlements worth up to $9 billion — behavior that courts and commentators have noted conflicts with a sincere belief that its products caused no harm.

Filing Deadlines — Statute of Limitations

Statutes of limitations for talc lawsuits vary by state and typically run from the date of a cancer diagnosis, not the date of product use. Most states allow between 2 and 4 years from the date of diagnosis to file a claim. Some states apply a discovery rule, meaning the clock starts when the plaintiff discovered, or reasonably should have discovered, that their cancer may have been caused by talc use.

Many potential claimants who believe the filing window has closed may still be within the limitations period under their state’s discovery rule. An experienced talc attorney can review the specific facts of each case to determine eligibility.

Family members of deceased talc victims may file wrongful death claims, subject to their own state-specific deadlines. Given the volume of claims and the active bellwether trials underway, many plaintiff attorneys recommend filing as soon as possible rather than waiting for a global settlement to materialize.

Similar to the strategic corporate decisions documented in the Mielle Organics hair oil lawsuit, where internal product safety awareness preceded public disclosure by years, the J&J talc case illustrates how institutional silence about product risks can persist long after internal knowledge is established.

What Plaintiffs Are Actually Going Through

Behind the MDL case count and the billion-dollar verdicts are tens of thousands of women who trusted a product they used from childhood. Most plaintiffs used Johnson’s Baby Powder for feminine hygiene for years or decades, often beginning in adolescence, based on J&J’s marketing of the product as gentle, safe, and doctor-recommended.

Women diagnosed with ovarian cancer face aggressive treatment regimens, including surgery, chemotherapy, and in many cases, recurrence. Mesothelioma, the cancer most directly linked to asbestos exposure, carries a median survival of 12 to 21 months from diagnosis. Plaintiffs in the California bellwether trials were the families of three women who died from ovarian cancer after decades of talc use, trusting J&J’s repeated assurances of product safety.

The litigation has also exposed racial disparities in harm. J&J’s own marketing records show the company disproportionately targeted Black women in its advertising for perineal talc use, the highest-risk application method. The 2021 National Council of Negro Women lawsuit specifically alleged deceptive marketing targeting communities that faced above-average exposure.

Lawsuits like the Tampax lead contamination lawsuit reveal a broader pattern of consumer products marketed to women containing undisclosed harmful substances — a pattern the J&J talc litigation has documented in greater depth than any similar case in American legal history.

Read These

• Workday AI discrimination lawsuit
• XRP SEC lawsuit
• Mielle Organics hair oil lawsuit
• Brita water filter lawsuit
• Tampax lead contamination lawsuit

What This Lawsuit Teaches Consumers

The Johnson & Johnson talc litigation is the clearest modern example of the gap between a corporation’s public safety claims and its private knowledge. For more than six decades, J&J marketed Baby Powder to mothers, women, and children as a product so gentle it was suitable for infants, while internal records show the company knew its talc supply could contain asbestos and took active steps to keep that information from regulators and the public.

The lawsuit teaches three enduring lessons about product safety and corporate accountability.

First, corporate concealment can outlast regulatory oversight. The FDA’s failure to detect the asbestos problem in J&J’s talc was not accidental. J&J lobbied for less sensitive testing methods and withheld lab results that showed contamination. Regulators can only act on information disclosed to them. When companies suppress internal testing, the regulatory safety net fails.

Second, trusted brands are not automatically safe products. J&J’s ability to sustain six decades of concealment depended in large part on its reputation as a family-friendly, trusted healthcare company. Consumers reasonably assumed that a product sold by a major pharmaceutical and consumer goods company and used by millions would have been rigorously tested for carcinogens. That assumption proved fatal for many of the women who filed claims.

Third, the civil litigation system remains one of the few mechanisms capable of surfacing corporate concealment at this scale. Three federal courts rejected J&J’s attempts to use bankruptcy to make the litigation disappear. Juries awarded billions in punitive damages specifically to punish the concealment, not merely to compensate plaintiffs for their injuries. The Lancet retraction of a 1977 study authored by a secret J&J consultant removed a pillar of the company’s scientific defense nearly fifty years after it was published.

For consumers, the practical takeaways are direct: check active MDL databases when a product faces mass tort litigation; understand that corporate settlement offers through bankruptcy are designed to minimize payouts rather than maximize justice; and do not assume that a product’s long commercial history or household-name status guarantees its safety. The J&J talc case demonstrates that neither reputation nor longevity can substitute for transparency.